ATG7 and neoplasm: Other studies have found that in human glioblastoma xenografts, knockdown of ATG7 combined with treatment with the VEGF-neutralizing antibody bevacizumab disrupted tumor growth and helped prevent tumor resistance to anti-angiogenic therapy [142].